We are very happy to announce that EAMDA, Parent Project Muscular Dystrophy and European Organisation for Rare Diseases – EURORDIS have signed a joint letter in January 2014 on the negative opinion on conditional approval of ataluren (Translarna) that was sent to the Committee for Medicinal Products for Human Use of the European Medicines Agency.
The joint effort resulted in that EMA granted conditional approval for ataluren.
